Alliancebernstein L.P. Ascendis Pharma A/S Transaction History

Alliancebernstein L.P.

$278 Billion
Q2 2024

A detailed history of Alliancebernstein L.P. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Alliancebernstein L.P. holds 475,001 shares of ASND stock, worth $68.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

475,001

Previous 473,753 0.26%

Holding current value

$68.7 Million

Previous $71.6 Million 9.55%

% of portfolio

0.02%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $151,095 - $191,780	1,248 Added 0.26%	475,001 $64.8 Million
Q1 2024 May 14, 2024	SELL	$123.45 - $159.4 $14.2 Million - $18.4 Million	-115,183 Reduced 19.56%	473,753 $71.6 Million
Q4 2023 Feb 14, 2024	SELL	$86.1 - $127.36 $1.2 Million - $1.78 Million	-13,938 Reduced 2.31%	588,936 $74.2 Million
Q3 2023 Nov 14, 2023	BUY	$86.5 - $103.97 $2.12 Million - $2.55 Million	24,487 Added 4.23%	602,874 $56.5 Million
Q2 2023 Aug 15, 2023	BUY	$69.96 - $97.84 $4.43 Million - $6.2 Million	63,329 Added 12.3%	578,387 $51.6 Million
Q1 2023 May 15, 2023	BUY	$104.9 - $126.78 $2.63 Million - $3.18 Million	25,112 Added 5.13%	515,058 $55.2 Million
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $14.9 Million - $19.8 Million	-149,930 Reduced 23.43%	489,946 $59.8 Million
Q3 2022 Nov 15, 2022	SELL	$84.03 - $110.23 $3.69 Million - $4.84 Million	-43,920 Reduced 6.42%	639,876 $66.1 Million
Q2 2022 Aug 15, 2022	SELL	$78.08 - $117.61 $1.96 Million - $2.95 Million	-25,085 Reduced 3.54%	683,796 $63.6 Million
Q1 2022 May 13, 2022	SELL	$102.18 - $135.75 $129,870 - $172,538	-1,271 Reduced 0.18%	708,881 $83.2 Million
Q4 2021 Feb 14, 2022	BUY	$127.1 - $169.66 $19.3 Million - $25.8 Million	152,221 Added 27.28%	710,152 $95.5 Million
Q3 2021 Nov 10, 2021	SELL	$112.67 - $176.92 $2.76 Million - $4.33 Million	-24,467 Reduced 4.2%	557,931 $88.9 Million
Q2 2021 Jul 30, 2021	BUY	$121.62 - $145.29 $12.5 Million - $15 Million	103,056 Added 21.5%	582,398 $76.6 Million
Q1 2021 May 06, 2021	BUY	$124.92 - $173.33 $2.1 Million - $2.91 Million	16,809 Added 3.63%	479,342 $61.8 Million
Q4 2020 Feb 08, 2021	SELL	$151.2 - $182.76 $902,361 - $1.09 Million	-5,968 Reduced 1.27%	462,533 $77.1 Million
Q3 2020 Nov 12, 2020	BUY	$134.29 - $154.32 $2.88 Million - $3.31 Million	21,467 Added 4.8%	468,501 $72.3 Million
Q2 2020 Aug 13, 2020	SELL	$110.87 - $156.01 $6.23 Million - $8.77 Million	-56,223 Reduced 11.17%	447,034 $66.1 Million
Q1 2020 May 14, 2020	SELL	$97.01 - $145.11 $3.28 Million - $4.91 Million	-33,829 Reduced 6.3%	503,257 $56.7 Million
Q4 2019 Feb 18, 2020	BUY	$91.45 - $139.12 $177,413 - $269,892	1,940 Added 0.36%	537,086 $74.7 Million
Q3 2019 Nov 14, 2019	BUY	$95.8 - $118.9 $3.04 Million - $3.77 Million	31,741 Added 6.31%	535,146 $51.5 Million
Q2 2019 Aug 14, 2019	SELL	$107.11 - $132.09 $11.5 Million - $14.2 Million	-107,449 Reduced 17.59%	503,405 $58 Million
Q1 2019 May 14, 2019	SELL	$62.15 - $129.99 $4.71 Million - $9.85 Million	-75,790 Reduced 11.04%	610,854 $71.9 Million
Q4 2018 Feb 13, 2019	SELL	$55.16 - $69.67 $1.53 Million - $1.93 Million	-27,722 Reduced 3.88%	686,644 $43 Million
Q3 2018 Nov 08, 2018	BUY	$63.77 - $76.28 $1.21 Million - $1.45 Million	19,039 Added 2.74%	714,366 $50.6 Million
Q2 2018 Aug 13, 2018	SELL	$58.55 - $73.92 $2.23 Million - $2.81 Million	-38,056 Reduced 5.19%	695,327 $46.3 Million
Q1 2018 May 14, 2018	BUY	$38.98 - $68.04 $26.4 Million - $46.1 Million	677,843 Added 1220.46%	733,383 $48 Million
Q4 2017 Feb 13, 2018	BUY	$31.98 - $40.38 $816,769 - $1.03 Million	25,540 Added 85.13%	55,540 $2.23 Million
Q3 2017 Nov 13, 2017	BUY	$26.89 - $37.1 $806,700 - $1.11 Million	30,000	30,000 $1.09 Million

Others Institutions Holding ASND

# of Institutions

223

Shares Held

56.5M

Call Options Held

142K

Put Options Held

259K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $8.07B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.

Account

Alliancebernstein L.P. Ascendis Pharma A/S Transaction History